Study Year of publication Study
design 		Patients/
implants 		ADs Gender Follow-up
perioda 		Survival rate of implants Survival rate of
suprastructures 		Crestal
bone lossa 		PI Success rate
n/n M/F Months % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n suprastructures) 		mm % (n/n patients)
% (n/n implants) 		% (n/n patients)
% (n/n implants)
Oczakir et al. [6] 2005 CS 1/4 OLP 0/1 72 100% (1/1)
100% (4/4) 		100% (1/1)
100% (1/1) 		NR 0% (0/1)
0% (0/4) 		NR
Aboushelib et al. [25] 2017 PS 23/55 OLP (active) 11/12 4 13% (3/23)
23.6% (13/55)
Early loss: 42
Late loss: 0 		NR Mean: 0.26 NR NR
Fu et al. [41] 2019 CR 1/4 OLPc 0/1 36 100% (1/1)
100% (4/4) 		100% (1/1)
100% (1/1) 		Range: 3 - 4 NR NR
Martin-Cabezas [52] 2021 CR 1/3 OLP 0/1 360 100% (1/1)
100% (3/3) 		NR NR 100% (1/1)
100% (3/3) 		NR
Anitua et al. [68] 2018 RS 23/66 OLP 3/20 Mean: 63 95.7% (22/23)
98.5% (65/66)
Early loss: 0
Late loss: 1 		NR Mesial: mean: 0.96
Distal: mean: 0.99 		NR NR
Czerninski et al. [69] 2013 RS 14/54 OLP 3/11 Range:
12 - 24 		100% (14/14)
100% (54/54)d 		NR NR NR 100% (14/14)
100% (54/54)h
Esposito et al. [80] 2003 CS 1/2 OLP 0/1 18 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 0% (0/1)
0% (0/2) 		100% (1/1)
100% (2/2)
1/2 OLP+pSS 0/1 18 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		0 0% (0/1)
0% (0/2) 		100% (1/1)
100% (2/2)g
Reichart [82] 2006 CS 1b/1 OLP 0/1 36 100% (1/1)
100% (1/1) 		NR NR NR NR
Hernández et al. [85] 2012 CCS 18/56 OLP 4/14 Median: 56.5 100% (18/18)
100% (56/56) 		NR Mean: 1.95 NR NR
18/62 Control group 6/12 Median: 52.5 NR
96.8% (60/62)
Early loss: 0
Late loss: 2 		NR Mean: 1.87 NR NR
Khamis et al. [86] 2019 CCS 20/NR OLPc,e NR 48 100% (20/20)
NR 		NR Mean: 0.76 NR NR
22/NR OLPc,f NR 48 100% (22/22)
NR 		NR Mean: 2.53 NR NR
17/NR Control group NR 48 100% (17/17)
NR 		NR Mean: 0.8 NR NR
López-Jornet et al. [88] 2014 CCS 16/56 OLP 6/10 Median: 42 NR NR NR NR
25% (14/56) 		NR
16/50 Control group 8/8 Median: 48 NR NR NR NR
16% (8/50) 		NR
Overall
OLP - CCS: 3
CS: 3
CR: 2
RS: 2
PS: 1 		142/303 - Ratio: 1/2.7 Mean: 43.6
Median: 48 		83.3% (105/126)
82.6% (204/247)
Of these: 97.7% (42/43) early loss 		100% (4/4)
100% (4/4) 		Mean: 1.05 25% (1/4)
25.4% (17/67) 		100% (16/16)
100% (58/58)g,h
OLP
+concomitant ADs 		- CS: 1 1/2 - Ratio: 0/1 Mean: 18 100% (1/1)
100% (2/2) 		100% (1/1)
100% (1/1) 		Mean: 0 0% (0/1)
0% (0/2) 		100% (1/1)
100% (2/2)g
Control group - CCS: 3 51/112 - Ratio: 1/1.4 Mean: 48
Median: 48 		100% (17/17)
96.8% (60/62)
Of these: 0% (0/2) early loss 		NR Mean: 1.85 NR
16% (8/50) 		NR

a = weighted mean or median; b = the remaining 2 patients in this CS were excluded from data extraction due to insufficient information; c = remission at implant placement; d = early loss NR; e = continued systemic glucocorticoids administration post implant placement; f = discontinued systemic glucocorticoids administration 12 weeks post implant placement; g = criteria by Esposito et al. [26]; h = criteria by Buser et al. [116].
ADs = autoimmune diseases; CCS = case-control study; CR = case report; CS = case series; M/F = male/female; N = number; NR = not reported; PI = peri-implantitis; PS = prospective study; pSS = primary Sjögren's syndrome; RS = retrospective study.